Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
100%
Infection
82%
Hepatitis C Virus
74%
Chronic Hepatitis C
73%
Placebo
70%
Liver Cirrhosis
61%
Hepatitis C
61%
Pharmacokinetics
54%
Sofosbuvir
52%
Hepatitis C Virus Genotype 1
50%
Adverse Event
49%
Nonalcoholic Fatty Liver
48%
Peginterferon
44%
Fibrosis
36%
Antivirus Agent
33%
Interferon
31%
Clinical Trial
26%
Daclatasvir
21%
Virus RNA
21%
Boceprevir
21%
Tolerability
17%
Ritonavir
17%
Metabolic Dysfunction-Associated Steatohepatitis
16%
Telaprevir
14%
Antiviral Drug
14%
Ledipasvir Plus Sofosbuvir
14%
Fatty Liver
13%
Proteinase Inhibitor
13%
Ombitasvir
12%
Peginterferon Alpha2a
12%
Moderate Hepatic Impairment
12%
Antiviral Activity
12%
Liver Disease
11%
Velpatasvir
11%
Asunaprevir
11%
Grazoprevir
10%
Monotherapy
10%
Elbasvir
10%
Paritaprevir
10%
Simeprevir
10%
Pharmacodynamics
10%
Alanine Aminotransferase
10%
Ledipasvir
9%
Hepatitis C Virus Genotype 2
9%
Chronic Kidney Failure
9%
Liver Fibrosis
9%
Nonstructural Protein 5A Inhibitor
9%
Mild Hepatic Impairment
9%
Hepatitis C Virus Genotype 3
9%
Obeticholic Acid
8%
Medicine and Dentistry
Nonalcoholic Fatty Liver
61%
Fibrosis
46%
Liver Cirrhosis
43%
Placebo
31%
Chronic Hepatitis C
22%
Ribavirin
18%
Sofosbuvir
17%
Hepatitis C
17%
Hepatitis C Virus
15%
Patient-Reported Outcome
15%
Infection
14%
Liver Fibrosis
13%
Primary Biliary Cirrhosis
10%
Clinical Trial
10%
Peginterferon
10%
Biopsy Technique
10%
Selonsertib
10%
Hepatitis C Virus Genotype 1
9%
Adverse Event
9%
Interferon
9%
Metabolic Dysfunction-Associated Steatohepatitis
8%
Steatosis
8%
Liver Histology
7%
Quality of Life
7%
Alanine Aminotransferase
6%
Telaprevir
6%
Liver Biopsy
6%
Disease Exacerbation
6%
Portal Hypertension
6%
Treatment Duration
6%
Liver Disease
5%
Pruritus
5%
Oral
5%
Diseases
5%
Transient Elastography
5%
Magnetic Resonance Imaging
5%
Fatty Liver
5%
Venous Pressure
5%
Immunology and Microbiology
Hepatitis C Virus
36%
Hepatitis C
33%
Infection
20%
Infectious Disease
19%
Steatohepatitis
17%
Hepatitis C Virus Genotype 1
16%
Ribonucleic Acid
16%
Cirrhosis
13%
Ribavirin
11%
Sofosbuvir
10%
Pretreatment
9%
NS5A
9%
Antiviral Activity
9%
Proteinase
8%
Protease
8%
NS5A Inhibitors
8%
Pharmacokinetics
7%
Hepatitis C Virus Genotype 4
6%
Multiple Drug Dose
6%
Interferon Type I
6%
NS5B
6%
Alanine
5%
Blood Plasma
5%
Ledipasvir
5%